Difference between revisions of "Team:AFCM-Egypt"
Aymanshafei (Talk | contribs) |
Aymanshafei (Talk | contribs) |
||
| Line 138: | Line 138: | ||
<ul id="afcmslides"> | <ul id="afcmslides"> | ||
<li class="afcmslide"> | <li class="afcmslide"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/b/bb/2-AFCM-Egypt-sponsers-EFIA_LOGO.png" style="width: | + | <img src="https://static.igem.org/mediawiki/2017/b/bb/2-AFCM-Egypt-sponsers-EFIA_LOGO.png" style="width: 150px;padding-right: 15px;"> |
<img src="https://static.igem.org/mediawiki/2017/b/bd/3-AFCM-Egypt-sponsers-Pharco_Logo.png" style="width: 150px;padding-right: 15px;"> | <img src="https://static.igem.org/mediawiki/2017/b/bd/3-AFCM-Egypt-sponsers-Pharco_Logo.png" style="width: 150px;padding-right: 15px;"> | ||
<img src="https://static.igem.org/mediawiki/2017/3/3b/4-AFCM-Egypt-sponsers-Nationel_Research.png" style="width: 150px;padding-right: 15px;"> | <img src="https://static.igem.org/mediawiki/2017/3/3b/4-AFCM-Egypt-sponsers-Nationel_Research.png" style="width: 150px;padding-right: 15px;"> | ||
| Line 144: | Line 144: | ||
</li> | </li> | ||
<li class="afcmslide"> | <li class="afcmslide"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/6/67/7-AFCM-Egypt-sponsers-Image-2.jpeg" style="width: | + | <img src="https://static.igem.org/mediawiki/2017/6/67/7-AFCM-Egypt-sponsers-Image-2.jpeg" style="width: 160px;padding-right: 15px;"> |
<img src="https://static.igem.org/mediawiki/2017/e/eb/6-AFCM-Egypt-sponsers-SimEra.png" style="width: 150px;padding-right: 15px;"> | <img src="https://static.igem.org/mediawiki/2017/e/eb/6-AFCM-Egypt-sponsers-SimEra.png" style="width: 150px;padding-right: 15px;"> | ||
<img src="https://static.igem.org/mediawiki/2017/3/37/5-AFCM-Egypt-sponsers-IDT.png" style="width: 150px;padding-right: 15px;"> | <img src="https://static.igem.org/mediawiki/2017/3/37/5-AFCM-Egypt-sponsers-IDT.png" style="width: 150px;padding-right: 15px;"> | ||
Revision as of 01:13, 17 October 2017
Abstract
Knock-in of Circular RNA gene in Hepatocellular Carcinoma cells via CRISPR/Cas9
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers
in males and next to breast cancer among females in Egypt - based upon results of National Cancer Registry Program of Egypt-.
"Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique
that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma.
This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials.
This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers in males and next to breast cancer among females in Egypt - based upon results of National Cancer Registry Program of Egypt-. "Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma. This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials. This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.
AFCM-Egypt
We strive to excel
click here
